Disease · MONDO_0001824

polyneuropathy

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. polyneuropathy. Diseases, record MONDO_0001824. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0001824

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: polyneuropathy; Open Targets
Open Targets ID: MONDO_0001824; Open Targets
Disease Ontology: DOID:1389; Disease Ontology
MeSH: D011115; MeSH
NCI Thesaurus: C26951; NCI Thesaurus
Highest stage of its drugs: Approval, for 6 of its 13 drugs, from DailyMed, FDA and PMDA; Open Targets

Drugs13

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
PATISIRAN SODIUM	CHEMBL4297536	Oligonucleotide	Approval	DailyMed and PMDA	2	0	0	Drugs and targets
VUTRISIRAN SODIUM	CHEMBL5095303	Oligonucleotide	Approval	FDA and PMDA	2	0	0	Drugs and targets
EPLONTERSEN SODIUM	CHEMBL4594335	Oligonucleotide	Approval	FDA	1	0	0	Drugs and targets
INOTERSEN SODIUM	CHEMBL4297537	Oligonucleotide	Approval	DailyMed	1	0	0	Drugs and targets
TAFAMIDIS MEGLUMINE	CHEMBL2105675	Small molecule	Approval	PMDA	1	0	0	Drugs and targets
VUTRISIRAN	CHEMBL4594511	Oligonucleotide	Approval	FDA	1	0	0	Drugs and targets
PATISIRAN	CHEMBL3989987	Oligonucleotide	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
RITUXIMAB	CHEMBL1201576	Antibody	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
CAPSAICIN	CHEMBL294199	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
INOTERSEN	CHEMBL4297770	Oligonucleotide	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 13

See all 13 drugs

Targets16

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
TTR	Transthyretin	8	Transthyretin mRNA RNAi inhibitor; Transthyretin mRNA antisense inhibitor; Transthyretin mRNA rnai inhibitor; Transthyretin stabiliser	Approval	https://conductscience.org/library/genes/7276	Drugs and targets
BTK	Tyrosine-protein kinase BTK	1	Tyrosine-protein kinase BTK inhibitor	Phase 2	https://conductscience.org/library/genes/695	Drugs and targets
CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1B	1	Voltage-gated N-type calcium channel alpha-1B subunit blocker	Phase 2	https://conductscience.org/library/genes/774	Drugs and targets
MS4A1	B-lymphocyte antigen CD20	1	B-lymphocyte antigen CD20 binding agent	Phase 3	https://conductscience.org/library/genes/931	Drugs and targets
SCN10A	Sodium channel alpha subunit	1	Sodium channel alpha subunit blocker	Phase 2/3	https://conductscience.org/library/genes/6336	Drugs and targets
SCN11A	Sodium channel alpha subunit	1	Sodium channel alpha subunit blocker	Phase 2/3	https://conductscience.org/library/genes/11280	Drugs and targets
SCN1A	Sodium channel alpha subunit	1	Sodium channel alpha subunit blocker	Phase 2/3	https://conductscience.org/library/genes/6323	Drugs and targets
SCN2A	Sodium channel alpha subunit	1	Sodium channel alpha subunit blocker	Phase 2/3	https://conductscience.org/library/genes/6326	Drugs and targets
SCN3A	Sodium channel alpha subunit	1	Sodium channel alpha subunit blocker	Phase 2/3	https://conductscience.org/library/genes/6328	Drugs and targets
SCN4A	Sodium channel alpha subunit	1	Sodium channel alpha subunit blocker	Phase 2/3	https://conductscience.org/library/genes/6329	Drugs and targets

1 to 10 of 16

See all 16 targets

Trials10

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01960348	APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis	Phase 3	225	2018-09-06	TTR-mediated Amyloidosis, Amyloidosis, Hereditary, Amyloid Neuropathies, Familial, Familial Amyloid Polyneuropathies, Amyloid Neuropathies, Amyloidosis, Hereditary, Transthyretin-Related	PATISIRAN	Its record names the disease	ClinicalTrials.gov
NCT01737398	Efficacy and Safety of Inotersen in Familial Amyloid Polyneuropathy	Phase 2/3	173	2019-01-23	FAP, Familial Amyloid Polyneuropathy, TTR, Transthyretin, Amyloidosis	INOTERSEN	Its record names the disease	ClinicalTrials.gov
NCT00064623	Study of NGX-4010 for the Treatment of Painful HIV-Associated Neuropathy	Phase 3	300		HIV Infections, Peripheral Nervous System Diseases, Pain	CAPSAICIN	Its record names the disease	ClinicalTrials.gov
NCT04647877	Phenytoin Cream for the Treatment of Neuropathic Pain	Phase 2/3	81		Chronic Idiopathic Axonal Polyneuropathy	PHENYTOIN	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT04201418	A Multicenter Observational Study to Evaluate the Effectiveness of Patisiran in Patients With Polyneuropathy of ATTRv Amyloidosis With a V122I or T60A Mutation		67		Hereditary Transthyretin-mediated (ATTRv) Amyloidosis, Polyneuropathy	PATISIRAN	Its record names the disease	ClinicalTrials.gov
NCT00259974	RIMAG Study: Trial of Rituximab Versus Placebo in Polyneuropathy Associated With Anti-MAG IgM Monoclonal Gammopathy	Phase 3	60		Polyneuropathy	RITUXIMAB	Its record names the disease	ClinicalTrials.gov
NCT05939037	Zanubrutinib Treatment in Patients With IgM Monoclonal Gammopathy and Antri-MAG Related Polyneuropathy	Phase 2	35		Monoclonal Gammopathy of Uncertain Significance	RITUXIMAB, ZANUBRUTINIB	Its record names the disease	ClinicalTrials.gov
NCT00156689	A Study to Determine if Levetiracetam Will Assist Those Suffering From Chronic Idiopathic Axonal Polyneuropathy.	Phase 2	30		Chronic Idiopathic Axonal Polyneuropathy	LEVETIRACETAM	Open Targets' reading of its record	ClinicalTrials.gov
NCT05023889	Spectrum of Peripheral and Autonomic Neuropathies in Patients With aTTRwt Amyloidosis and Response to Patisiran Therapy	Early phase 1	10		Polyneuropathies, Wild Type ATTR Amyloidosis, Wild-Type Transthyretin-Related (ATTR)Amyloidosis, Wild-Type Transthyretin Cardiac Amyloidosis, Transthyretin Amyloidosis	PATISIRAN	Its record names the disease	ClinicalTrials.gov
NCT00006072	A Study of Rituxan in the Treatment of Polyneuropathies Associated With Serum IgM Autoantibodies	Phase 2			Peripheral Neuropathy	RITUXIMAB	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials4

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Patisiran (ALN-TTR02) vs Placebo: deaths from any cause	7 of 148	6 of 77	225	NCT01960348	Trial comparisons
Patisiran (ALN-TTR02) vs Placebo: serious adverse events	54 of 148	31 of 77	225	NCT01960348	Trial comparisons
Inotersen vs Placebo: deaths from any cause	5 of 112	0 of 60	172	NCT01737398	Trial comparisons
Inotersen vs Placebo: serious adverse events	36 of 112	13 of 60	172	NCT01737398	Trial comparisons

Papers from its trials25

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
29972757	RESULT	1	PubMed
41937511	DERIVED	1	PubMed
41913562	DERIVED	1	PubMed
38548524	DERIVED	1	PubMed
38065307	DERIVED	1	PubMed
36273216	DERIVED	1	PubMed
36120830	DERIVED	1	PubMed
35799473	DERIVED	1	PubMed
35766224	DERIVED	1	PubMed
34355354	DERIVED	1	PubMed

1 to 10 of 25

See all 25 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0001824

GET https://conductscience.org/api/diseases/v1/MONDO_0001824/papers?page=2

API reference For AI assistants